This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Even if the financial resources were available, there aren’t enough human resources in pharmacy to provide high-touch engagement to the millions of patients who suffer from common chronic diseases.
The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.
AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class. Qulipta (atogepant) is already approved for prevention of episodic migraine – where attacks are less frequent – getting the green light from the FDA last September for this use a few months after Biohaven and Pfizer’s Nurtec ODT (rimegepant).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioMarin Pharmaceutical has obtained Japan’s Ministry of Health, Labor and Welfare (MHLW) approval of the registration for its Voxzogo (vosoritide) for injection to treat achondroplasia in children whose growth plates are not closed. A modified C-type natriuretic peptide (CNP), Voxzogo acts on achondroplasia’s underlying pathophysiology. It works by down-regulating fibroblast growth factor receptor 3 (FGFR3) signalling and subsequently boosting endochondral bone formation.
Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.
123
123
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.
As a physician, you are required to complete CME activities in order to maintain your certification. However, with so many CME activity types available, it can be difficult to select the activity that works best for you. Many providers offer enduring materials to help practitioners fulfill these requirements. What are CME enduring materials? How do you know if they are best for meeting your CME requirements?
Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses how patients who have experienced a loss of taste and smell following COVID-19 infection may be impacted by this symptom for years without realizing it.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Imlunestrant is currently under investigation as monotherapy or in combination with other anticancer therapies for patients with estrogen receptor-positive, locally advanced or metastatic breast cancer and endometrial cancer.
The company has introduced a mobile application designed to streamline and automate training in a single platform for sponsors, CROs, and research sites.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. The litigation revolves around US Patent No. 9,187,405, granted in 2015, which covers a dosing regimen for Gilenya (fingolimod) in relapsing-remitting MS. Gilenya is Novartis’ third-biggest product and the top seller in its neuroscience franchise, bringing in revenues of almost $2.8 billion in 2021, although sales have st
I am going to outline a common case of escalating dosages of levothyroxine. I beg you to ALWAYS look for binding interactions with levothyroxine when you see dose increases! KE is a 68-year-old female with a history of GERD, anemia, osteoarthritis, hypertension, and diabetes. Her current medication list includes: Metformin 500 mg TID Ferrous sulfate […].
The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and regulatory inspections became difficult to carry out. Ben Hargreaves finds out how the issue of foreign manufacturing has become a major US political talking point and how this could influence the pressures facing the industry. In a global economy, across a number of industries, low-margin products are often manufactured in countries where labour is cheap.
In October 2021, the World Health Organization (WHO) announced a target of fully vaccinating 70% of each country’s population against Covid-19 by the end of June 2022. At the time, while many high-income countries had already surpassed this goal, Covid-19 vaccination programmes in developing nations, particularly in Sub-Saharan Africa, had barely begun.
Cheers to THE largest sale of the year for one of my favorite skin care brands! 50% off with code THELUXEPHARMACIST is happening for ONE DAY ONLY June 23rd so act fast! FRÉ always has a money back guarantee so you truly have nothing to lose. I started using FRÉ products this winter and quickly fell in love with them. I have seen great results with these products which I’ll share more about below.
Six in 10 respondents to Health Union’s Spondyloarthritis In America 2021 survey said they feel other people in their lives don’t understand the risks of being immunocompromised. And they aren’t alone. Scientists estimate nearly 3% of people in the U.S. can be considered immunocompromised, meaning their immune system and their ability to fight infections and other diseases is weakened.
Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.
Pfizer has harnessed the expertise of health data specialist Truveta to provide close monitoring of safety and other signals for its products, including COVID-19 vaccine Comirnaty, almost in real-time. Truveta’s platform is based on electronic medical record data – updated daily – for more than 50 million people in the US, harvesting anonymised patient care information from tens of thousands of clinical care sites across 42 states.
Vaccinations are a critical preventive vaccinations are a critical preventive health measure and are routinely recommended from an early age. Indeed, the first hepatitis B vaccine in the series can be administered within 12 to 24 hours of birth.
Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the centrepiece of a 10-year agreement-in-principle between the biotech and the UK government – which has been rumoured to be on the cards for several months – that is worth in the region of £1 billion ($1.2 billion), according to a report in the Financial Times.
Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple runners in the running. One of these – dubbed V116 – is a cocktail of 21 Streptococcus pneumoniae serotypes designed to have the most benefit in adult populations, and it has just cleared a phase 1/2 trial as it embarks on a phase 3 programme.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content